AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06103422 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Localized taste tests
Description: Patients who underwent Le Fort I osteotomy, Sagittal Split Ramus Osteotomy, and Bimaxillary Surgeries were asked to identify the quality of 4 basic taste modalities preoperatively and at postoperative 1st, 3rd, and 6th months by administering localized taste tests. In the localized mouth taste test, the highest concentration solution of one of the four flavors was administered. In each application, 0.25 ml of solution was absorbed on a sterile cotton swab and applied on 6 test areas on the palate and tongue.
Study NCT05781529 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar ridge augmentation with injectable platelets rich fibrin
Description: Injectable platelets rich fibrin is added to xenograft for alveolar ridge augmentation in order to preserve bone and decrease bone resorption
Study NCT02529956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB4940
Description: * Active Substance: UCB4940~* Pharmaceutical Form: Solution for infusion~* Concentration: 80 mg/ml~* Route of Administration: Intravenous use
Study NCT02529956 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Active Substance: Placebo~* Pharmaceutical Form: Solution for infusion~* Concentration: 0.9 % sodium chloride aqueous solution~* Route of Administration: Intravenous use
Study NCT01258985 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tai Chi
Description: 12 weeks of Tai Chi
Study NCT01258985 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: 6 weeks of individualized Physical Therapy followed by 6 weeks of supervised Home Exercise
Study NCT04361331 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lenvatinib combined with gemox
Description: Arm2: Lenvatinib + gemox
Study NCT04361331 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Toripalimab combined with lenvatinib
Description: Toripalimab combined with lenvatinib
Study NCT02980458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone 500Mg Tablet
Study NCT02980458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferiprone 500 MG Oral Tablet [Ferriprox]
Study NCT02842385 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implant
Description: One or two stages of implants within thin and thick gingiva were monitored 1.5 year after placement
Study NCT03030534 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Educational package and software package
Description: Using Information and communication technology to deliver health promoting activities
Study NCT03030534 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health promotion tips
Description: Give general information on health promotion
Study NCT03906708 — intervention group
Intervention type: OTHER
Intervention: Diffusion Capacity of the Lung for Carbon Monoxide (DLCO)
Description: Infant lung function testing
Study NCT03728985 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis
Description: Endovascular Aortic Stent-Graft
Study NCT03728985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis
Description: Endovascular Aortic Stent-Graft
Study NCT01016041 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: everolimus stent
Description: stenting
Study NCT01016041 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel stent
Description: stenting
Study NCT04644445 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bariatric Full Liquid Diet
Description: Patient's will receive a Bariatric Full Liquid Diet (standard bariatric clear liquid diet + protein shakes) to be started 4 hours after surgery
Study NCT01139840 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D2
Description: Study Supplement
Study NCT01139840 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3
Description: Study Supplement
Study NCT04369170 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: prosthesis connected directly to the implants
Description: dental prostheses connected directly to the dental implants
Study NCT04369170 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intermediate abutment
Description: dental prostheses connected with an intermediate abutment to the implant
Study NCT02514317 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous treatment
Study NCT02514317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Study NCT04019418 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Maltodextrin (carbohydrate)
Description: A drink containing 300ml of water and 75g of maltodextrin
Study NCT04019418 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Maltodextrin (carbohydrate)
Description: A drink containing 300ml of water and 75g of maltodextrin
Study NCT02420314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: * Administered intravenously (IV)~* Prescribed at 200 mg/m2 (standard dose)~* Given once every 21 days (i.e., one cycle)~* Up to 4 cycles are administered depending on disease response
Study NCT02420314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: * Administered intravenously (IV)~* Prescribed at AUC = 6 using the Cockcroft-Gault formula (standard dose)~* Given once every 21 days (i.e., one cycle)~* Up to 4 cycles are administered depending on disease response
Study NCT02420314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: * Administered intravenously (IV)~* 75g per infusion~* Two infusions per week~* 1 cycle is 3 weeks~* given up to 4 cycles~* may be given while chemotherapy if delayed due to low counts
Study NCT06211218 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cornea diseases diagnosed by artificial intelligence algorithm
Description: An artificial intelligence algorithm was applied to diagnose cornea diseases from slit-lamp images.
Study NCT04331951 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Targeted biopsy within Sydney protocol
Description: Biopsy at suspicious GIM lesions at any area of antrum (both lesser and greater curvature site), body (both lesser and greater curvature site) and incisura. If there is no abnormal mucosa seen at any site, random biopsy will be performed.
Study NCT02594579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 100,000 u per day on day 1,3 then 50,000 u/day on day 5,7,9,12 and continue 50,000 u 3 times/ week for 4 weeks
Study NCT02594579 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo on day 1,3,5,7,9,12 then 3 times/ week for 4 weeks
Study NCT04286776 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct electrical stimulation
Description: Stimulation will not exceed 0.75 mA and will be approved prior by study investigators. Each subject will have a safety threshold testing at the beginning of each session and if 'afterdischarges' occur the subject's stimulation threshold will be lowered.
Study NCT00680914 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK1024850A (Synflorix)
Description: 3 doses administered intramuscularly.
Study NCT00680914 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar
Description: 3 doses administered intramuscularly.
Study NCT00680914 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals' Hiberix™
Description: 3 doses administered intramuscularly.
Study NCT00680914 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Hiberix™
Description: 3 doses administered intramuscularly.
Study NCT00389480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-67 (formerly DB-67)
Description: infusion daily x 5 days, every 21 days
Study NCT01663363 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LASIK correction of myopic refractive errors
Description: Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System
Study NCT06036264 — intervention group
Intervention type: OTHER
Intervention: Collected of Datas
Description: age, sex, mode of dialysis, emergency context, approach, date of creation of the arteriovenous fistula (if concerned), date of start of dialysis, transplant status, date of registration on the renal transplant waiting list (if concerned), nephrologist, date of first consultation with the pre-nurse in advanced practice (APN) (if concerned)
Study NCT06036264 — intervention group
Intervention type: OTHER
Intervention: semi-structured interview
Description: Semi-structured interviews will be realized. The goal is to establish a qualitative analysis of the relevance and organization of pre-transplant assessments, of the reactivity in the adjustment of requests and assessments, and to identify the strong points or areas for improvement.
Study NCT01091883 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exablate treatment
Description: MR Guided Focused Ultrasound
Study NCT01091883 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: External Beam Radiation
Study NCT05995561 — intervention group
Intervention type: OTHER
Intervention: no intervention is planned.
Description: no intervention is planned.
Study NCT00257933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone high dose
Description: 4 mg/kg/day orally divided every 6 hours (maximum 30 mg per dose)
Study NCT00257933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone lower dose
Description: 2 mg/kg/day orally divided q 12 (maximum 30mg/dose) alternating with placebo
Study NCT04097665 — intervention group
Intervention type: DEVICE
Intervention: indocyanine green angiography
Description: All patients treated with expanded flaps will be assessed by surgeons, and the possible area of necrosis will be marked based on clinical experience. This area will be further divided into perfusion units (1\*1 square centimeter for each), and the center of each perfusion unit will be marked. Then all patients will receive ICGA after the complete transfer of flap to the recipient site. For ICGA, a 2ml bolus of indocyanine green (2.5mg/ml) was injected through the patient's intravenous line. The detector/camera of the SPY imaging system should place over the flap at approximately 30cm for fluorescence image acquisition. The fluorescence value will be recorded afterwards.
Study NCT04019418 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 30 minutes on a cycle ergometer working at 75% VO2 max
Study NCT04019418 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: 30 minutes on a cycle ergometer working at 75% VO2 max
Study NCT02011529 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TEAMcare treatment of diabetes
Description: TEAMcare is an evidence-based collaborative care approach to the treatment of diabetes and psychiatric illness. It involves structured visits with a study nurse to monitor psychiatric symptoms, control of medical disease, and self-care activities. The nurses use motivational coaching to help patients solve problems and set goals for improved self-care and medication adherence. Medications for diabetes, hypertension, and hyperlipidemia are monitored and therapy intensified based on treat-to-target guidelines. All of these process and outcome measures are tracked in a registry designed for the study, and the nurses receive weekly supervision with a psychiatrist, an endocrinologist and a psychologist in order to review new cases and to track progress. Once a patient achieves targeted levels for relevant measures, the patient and the nurse develop a maintenance plan.
Study NCT05781529 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar ridge augmentation with hyaluronic acid
Description: Hyaluronic is added to xenograft for alveolar ridge augmentation in order to preserve bone and decrease bone resorption
Study NCT05781529 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar ridge augmentation with xenograft
Description: Xenograft is added alone as a active compatator
Study NCT04287751 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CheckMeO2 Oximeter
Description: Simultaneous recording with a current standard oximeter (Minolta i300) and prolonged recording device. Comparison of data from first night and incidence of obstructive sleep apnoea identified from additional nights of recording identified.
Study NCT01630499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Lifestyle Intervention (TLI)
Description: The intervention is a nutrition, physical activity, and behavioral weight management program that is tailored to the specific needs of breast cancer survivors.
Study NCT01550887 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: No intervention
Description: No intervention will be performed on this study
Study NCT04019418 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rest
Description: 30 minutes laying on a bed
Study NCT04019418 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rest
Description: 30 minutes laying on a bed
Study NCT04019418 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: A drink containing 300ml of water
Study NCT04019418 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: A drink containing 300ml of water
Study NCT04138888 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Olmesartan Medoxomil/Hydrochlorothiazide 40 Mg/25 Mg film-coated tablets for oral use
Description: Olmesartan Medoxomil/Hydrochlorothiazide is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 40 mg of olmesartan medoxomil and 25 mg of hydrochlorothiazide.
Study NCT04138888 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Olmetec® Plus 40 Mg/25 Mg film-coated tablets for oral use
Description: Olmetec® Plus is manufactured by Daiichi Sankyo Europe GmbH, Germany. Each tablet contains 40 mg of olmesartan medoxomil and 25 mg of hydrochlorothiazide.
Study NCT04185532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rebound ACL brace and physioterapy
Description: Usage of rebound ACL brace and physioterapy supervised by physioterapist
Study NCT04185532 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physioterapy
Description: Physioterapy supervised by physioterapist
Study NCT01764035 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body Scan (BS) Meditation Intervention
Description: This intervention consists of 4 individual 60-minute sessions (week 1, 2, 4, and 6) in which participants learn the body scan meditation exercise and practice it at home, daily, lying in bed at their usual bedtime after going to bed (and when waking up at night, unable to go back to sleep). The Body-Scan meditation consists of a 30-minute exercise during which participants are guided to focus their attention on certain parts of their body (e.g. toes, feet). The core skill involves gradually adopting an observant, non-judgmental, and accepting stance towards bodily sensations, including feelings and thoughts.
Study NCT01764035 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Supportive Psychotherapy (SP)
Description: SP is a common form of non-specific psychotherapy available to patients with bipolar disorder in the community. It focuses on addressing a patient's current concerns, supporting a patient's adaptive coping skills, improving self-esteem, and expressing feelings and the therapeutic alliance. Using a conversational style, SP involves conveying empathy, validation, comforting and supporting patients in coping with distress about current life issues as well as providing encouragement and praise, clarification and opportunity to vent. SP will match BS in length, number of sessions and delivery schedule (four, 60-minute sessions, week 1, 2, 4, 6).
Study NCT02680899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Curricular Intervention
Description: The intervention is a novel grades 7 and 8 InSciEd Out curriculum in mental health and addiction called My Mind, My Body.
Study NCT03989479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brushing demonstration using T shaped toothbrush
Description: Brushing demonstration given at baseline and reinforced at 2 weeks and 1 month
Study NCT03989479 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brushing demonstration using conventional toothbrush
Description: Brushing demonstration given at baseline and reinforced at 2 weeks and 1 month
Study NCT03460704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMS
Description: 1 MIU equivalent to 80 mg colistimethate sodium diluted in 1 mL saline solution 0.45%. Investigational Medicinal Product (IMP) glass vials were shrink wrapped in opaque white plastic and provided in boxes of 30 vials (two weeks of b.i.d. dosing).~The 1 MIU/ml CMS/0.45% saline solution was transferred from the glass vial into a specific nebuliser system fitted with a 0.3 mL medication chamber, for administration by inhalation. This delivered a nominal dose of 0.3 MIU/24 mg CMS (11 mg CBA) from the device.~The first dose of the IMP was administered at the site under the supervision of the site staff and subjects were instructed how to prepare and self-administer the IMP at home via a specific nebuliser system, b.i.d. (morning and evening) over aperiod of 12 month.~At least 10 minutes (min) before each administration, an inhaled short-acting bronchodilator (e.g. salbutamol/albuterol), supplied by the Sponsor, could be taken to improve tolerability.
Study NCT03460704 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mL saline solution 0.45%. The placebo was made up of identical empty glass vials to which the same saline solution diluent was added in exactly the same way as the reconstitution of the active treatment by injecting the diluent through the rubber stopper. The glass vials were shrink wrapped with opaque white plastic to mantain the blind.
Study NCT01299961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abatacept
Description: 125 mg once a week up to 12 months.
Study NCT04719312 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Y modification of transconjunctival approach
Description: Section of the orbital septum is done at the Arcus Marginalis and subperiosteal dissection done to expose the infraorbital rim and orbital floor.~Subsequently, canthotomy of the superficial limb of the lateral canthal ligament is performed and subperiosteal dissection is carried out to expose the fracture at the frontozygomatic region.~The cutaneous Y will transform into a box when retracting its corners, increasing the working area and allowing access of the frontozygomatic (FZ) suture, lateral orbital wall, body of the zygoma, infraorbital rim, and floor of the orbit with a single approach.~A small upper vestibular incision is placed to expose the fracture at the zygomatic buttress. Reduction and fixation of fractures in a regular fashion are accomplished.
Study NCT01162785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 721015
Description: Intravesical SCH 721015 (on Day 1 and 4) at a dose concentration of 3x1011particles/mL given in a 75 mL total volume. Administered into bladder through a urinary catheter, 75 mL will be instilled, left in the bladder for 1 hour, plus or minus 10 minutes. During the dwell time, subject will be repositioned from left to right, back and abdomen to maximize bladder surface exposure, approximately every 15 minutes.
Study NCT03538808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Participants will be provided varenicline medication
Study NCT03538808 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be provided placebo medication
Study NCT03531541 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Application of TENS
Description: The subject's skin will be cleaned with mild soap and water. Two square self-adhesive electrodes (5x5cm) will be placed 1 cm below the olecranon of the ulna and 10 cm above the radiocarpal joint of the dominant hand, maintaining the PPT measurement region between two electrodes. Two identical TENS units will be used: an active and a placebo (Neurodyn Portable TENS, IBRAMED). The active unit will be applied with the patient in a supine position at a high frequency of 100 Hz, and pulse duration of 100 µs. Strong but comfortable intensity as dictated by each subject will be applied for 20 minutes. Participants will be asked about the intensity of TENS every 5 minutes, and if the intensity has faded, the intensity will be increased again to a strong but comfortable level.
Study NCT03531541 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CJM
Description: The examiner 3, who is responsible for cervical joint manipulation, will enter the room and stand at the head of the patient. Using the middle phalanx of the second finger of one hand, the examiner will apply pressure laterally on the joint processes of C6 and C7 vertebrae; the examiner will cradle the patient's opposite side with the other hand and then perform an ipsilateral inclination towards the C6, C7 segments, followed by a contralateral rotation to the tissue barrier to perform a high-velocity low-amplitude manipulation (thrust). If the patient does not experience joint cavitation during the maneuver, two more attempts will be made. If no sound occurs on the third attempt, the joints will be considered manipulated.